opultena.. ukog have over 10 bill shares./88 over 7 bill. neither have a fully funded drill or company.. we are very very cheap at .4 .. if it drops many will take them/. lots of sp moving news is coming..stll see us being 0.5/7 end of july. 250 mill dilution is nothing bearing in mind a weeks ago it would of been 1.4 billion
one can only assume that to deliver the next returns, stable cash flow was needed. For me it is great news (although i wish we had waited for the psc/contract news) so I wonder if mr B will come back? A lot less than the 1.4 billion dilution that we had. was taken privately so that was great. hopefully now fully funded for the drill.
Calgary, Canada, June 23, 2020 - Canadian Overseas Petroleum Limited ("COPL" or the "Company") (XOP: CSE) & (COPL: LSE), an international oil and gas exploration and development company focused on sub-Sahara Africa, today announces that it has entered into agreements for a £700,000 common share placing (the "Placing") with three (3) investors at 0.3 Pence per common share ("Placing Price"). The Company has entered into a non-brokered subscription agreement with an Investor for £500,000 of the Placing, and has agreed to pay a finders fee of £35,000 cash and 12,500,000 common share purchase warrants exercisable for 24 months at a 30% premium to the Placing Price for this portion of the Placing. In addition, YA II PN, Ltd ("YA") and Riverfort Global Opportunities PCC ("RGO") have committed to participate in the Placing for £100,000 each, as disclosed in the Company's Press release of June 15, 2020, at the Placing Price. The Placing is conditional on admission of the Placing Shares to trading on the LSE which is anticipated to be on or around 2 July 2020.
The funds received by the Company from the Placing will cover general working capital and enable the Company to continue focusing on its Nigerian OPL 226 project as disclosed on June 4, 2020.
Arthur Millholland, President and CEO, commented: "The timing of this common share placing is appropriate given the recent movement in the Company's share price and associated high trading volumes in the London market. This is the next step to our recently announced Loan Agreement with YA and RGO, and it again confirms the quality of the Company's principal asset."
what a lot of trades today.. this was first time since news they had over 10 mill shares. They wanted a huge premium at 0.52 for 18 mill. gives a clear indication where mm know it is going. news in next few days.. then PSC by 10 july..
Dan did not make the sp go down. Why people want to play the man , not the ball. He is a founder. He has an amicable settlement. He will no doubt still be handing stuff over.
It matters not. What matters is seeing the results that are due imo. Proving up the tech and the kissie deal. All are due (esp 004). I agree with soup. Matters not as not our call is it.. We are where we are. Dajjas be better to be happy support is where it is imo. as i am! anyway sun shining. new chapter is beginning..
sp has held well at the 4p support. for that i am very happy. I agree with earlier comments. sometimes a new ceo can drive things. It certainly feels like the chris/kirk combination. Is more focused on the structures. There has ob been changes since them (fluer) . also the PR (no pod casts after last returns). I hope we will soon get some results /updates.
As we are thankfully such a low low cost model.. We can weather things. But none of us our invested for that. We want results.. Rightly so.
I am not selling mine ! we still cheap.. we will be worth 1 p very soon. When the drill goes onto site.. imo is the time.. the fomo will bring the herd. we know it is proven oil.. we also know psc due in 2 weeks. q1 due this week. ( i wonder what is in there now). essar contracts signed. then all the nnpc/dpr updates. exciting times ahead
I think the truth is many our happy the sp has held up. I liked dan. Maybe others did not. No point commenting further. He has gone, they have looked after him (as they should). I hope there is good comms between them all. He has so many shares it is in his interest to play ball.. As it is theirs.. so an accord!
Me I just now want to see nxp004 news.. then the kissie deal!
I am still a tad surprised. I liked dan. I can see others points re the team. The tech and the pipeline is not in doubt. Assume C. blackwell will now be leading the charge to close deals. At least he has a proven track record there. It looks to me as though dan has kept all his warrants (unlike DW). so this was all amicable. Just now hope that we are going to be getting good news ..on nxp004...
i think if anything those on the fence. That could of bought at 13/15/20/27/30 and have delayed. To keep watching us re rate to where we should be. Must be annoying to them... When the news arrives we will fly pat .4/5 imo.
Dr Joanne Holland, Chief Scientific Officer Joanne received her PhD in Chemistry from Leeds University. She joined the process R&D group at Millennium Pharmaceuticals before moving to a combined research and commercial role at Stylacats Ltd. After this Joanne worked for Medeor Pharma Ltd and Medeor Ltd undertaking commercial and scientific research on new business and investment opportunities. Joanne is a cofounder of Nuformix, and is responsible for R&D, intellectual property and regulatory issues.
Chris Blackwell, formerly CEO of Vectura Group Plc from February 2004 to June 2015, was appointed a Non-Executive Director with Nuformix plc on 10 May 2018. His primary role with Vectura was to refocus drug development capabilities from a research led biotechnology company to a commercially driven pharmaceutical development company. Chris initially joined GSK as a Clinical Pharmacologist post PhD studies at Bath,moving to Hoffman La-Roche as UK Director, Global ProjectManagement. At Scotia Pharma Ltd Chris served as Director of Drug Development and Executive Director. Chris is a non-executive Director of AGI Therapeutics plc.
Dr Karl Keegan, Non-Executive Director Karl has over 25 years of experience working in senior roles in the life sciences industry. He is currently Chief Executive Officer and Executive Board member at HOX Therapeutics Ltd, a private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes. Karl spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada. Since then, primarily in CFO roles, he has focused on corporate development, and has a successful track record of devising and implementing M&A and finance projects, delivering value across all aspects of business strategy, highlights include the sale of Minster pharmaceuticals plc to Proximagen plc, multiple financings to support a new strategy for Pharming Group NV and leadership of M&A deals at Vectura Group plc.